Condition: Urinary Stones · Prostate Cancer · Bladder Cancer · Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Urological diseases such as urinary stones, prostate cancer, and bladder cancer are very common and often require highly specialized diagnosis and treatment. Today, the quality of care can vary between doctors, and there are not enough urology specialists to meet patient demand. Artificial intelligence (AI) may help doctors make faster and more consistent decisions. This study aims to develop and test an AI-powered assistant called "UroAgent" that supports doctors in diagnosing and treating urological diseases. UroAgent is built on a large language model trained specifically for urology and is connected to tools that help it retrieve medical knowledge and analyze images. To build and test UroAgent, the research team will use 1,500 past patient records from 2010-2025 and collect 500 new patient cases for validation, for a total of 2,000 cases. This is an observational study: no patient's medical treatment will be changed because of it. The goal is to create a reliable AI tool that helps improve urological care for patients.
This description comes directly from the study's public registry record.
Mingzhou Dai · +86 19924684262 · daimzh3@mail2.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Shantou, Guangdong, China | Recruiting |
| Ganzhou People's Hospital | Ganzhou, Jiangxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07721935